Very small embryonic-like stem cells: A predictor synergizing with complement and inflammatory factors for immunoglobulin A nephropathy prognosis

Table 1 Comparison of clinical baseline data between end-stage renal disease patients and non-end-stage renal disease patients, mean ± SD/n (%)

Indicators	Non-ESRD (n = 224)	ESRD (n = 31)	t/χ2	P value
Sex
Male	115 (51.3)	16 (51.0)	0.001	0.977
Female	109 (48.7)	15 (49.0)
Age (years)	38.46 ± 5.79	39.72 ± 9.21	0.996	0.320
BMI (kg/m2)	23.42 ± 3.13	22.98 ± 2.19	0.756	0.450
History of hypertension	63 (28.13)	9 (29.03)	0.011	0.916
Systolic pressure	129.64 ± 21.31	132.45 ± 22.32	0.684	0.495
Diastolic pressure	83.14 ± 11.14	86.47 ± 9.72	1.583	0.115
Thrombocyte (× 109/L)	259.64 ± 45.87	267.91 ± 38.85	0.957	0.339
Neutrophil (× 109/L)	3.88 ± 0.83	3.92 ± 0.77	0.381	0.801
White blood cell (× 109/L)	6.29 ± 0.75	6.37 ± 0.81	0.543	0.588
Lymphocyte (× 109/L)	1.71 ± 0.33	1.73 ± 0.37	0.324	0.746
24-hour proteinuria (g/d)	1.28 ± 0.17	1.31 ± 0.20	0.859	0.391
Albumin (g/L)	37.49 ± 5.96	38.71 ± 5.28	1.082	0.280
Urea nitrogen (mmol/L)	5.26 ± 0.53	5.31 ± 0.62	0.492	0.62.
Creatinine (μmol/L)	102.64 ± 12.53	98.89 ± 7.79	1.619	0.107
Uric acid (μmol/L)	321.90 ± 33.48	344.85 ± 30.88	3.609	< 0.001a
Triglyceride (mmol/L)	1.59 ± 0.27	1.53 ± 0.19	1.178	0.240
Total cholesterol (mmol/L)	4.08 ± 0.57	4.26 ± 0.66	1.613	0.108
High-density lipoprotein cholesterol (mmol/L)	0.89 ± 0.13	0.87 ± 0.18	0.712	0.477
Low-density lipoprotein cholesterol (mmol/L)	3.74 ± 0.42	3.89 ± 0.51	1.810	0.071
Oxford classification
M1	183 (81.70)	27 (87.10)	0.546	0.460
E1	113 (50.45)	20 (64.52)	2.160	0.142
S1	133 (59.38)	11 (35.48)	6.323	0.012a
T1-2	85 (37.95)	12 (38.71)	0.007	0.935
C1-2	121 (54.02)	16 (51.61)	0.063	0.801

^aP < 0.05.

ESRD: End-stage renal disease; BMI: Body mass index.